pembrolizumab

Drug Overview

Pembrolizumab is a highly selective, humanized monoclonal antibody (IgG4 isotype) that functions as a Programmed Death receptor-1 (PD-1) blocking antibody. As a groundbreaking advancement in cancer immunotherapy, it works by restoring the body’s own immune system against tumor cells.

• Generic Name: Pembrolizumab
• US Brand Names: KEYTRUDA®
• Drug Class: Programmed Death Receptor-1 (PD-1) blocking antibody, Immune Checkpoint Inhibitor
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Approved for oncological indications across various cancers
  
  Pembrolizumab is a powerful immunotherapy for many cancers. Explore the amazing health benefits of this life-saving medical treatment now.

What Is It and How Does It Work? (Mechanism of Action)

Pembrolizumab is a biological therapeutic agent that targets the negative immunoregulatory human cell receptor PD-1 on T-cells.

• Molecular Target: The drug targets and binds directly to the Programmed Death receptor-1 (PD-1) receptor on T-cells.
• Cellular Impact: PD-1 naturally acts as an immune checkpoint or a “brake” on T-cell activity, typically engaged by its ligands, PD-L1 and PD-L2, which are often overexpressed by tumor cells. By binding to PD-1, pembrolizumab specifically blocks the interaction between PD-1 and both PD-L1 and PD-L2 ligands.
• Result (Immune Activation): Blocking this interaction prevents the inhibitory signal that normally downregulates T-cells, effectively reactivating exhausted T-cells and restoring T-cell-mediated immune responses against tumor cells. This process promotes T-cell proliferation and increases cytokine production.
• Bone Affinity: The drug’s high affinity for PD-1 preserves the T-cells’ ability to rely on glycolysis as their primary energy source, thereby sustaining their anti-tumor effector functions.

FDA-Approved Clinical Indications

Pembrolizumab has a wide range of FDA-approved indications, often requiring specific biomarker testing (e.g., PD-L1, MSI-H, or dMMR status).

Oncological Uses

• Melanoma: Treatment of unresectable or metastatic melanoma. Also, adjuvant treatment for Stage IIB, IIC, or III melanoma following complete resection.
• Non-Small Cell Lung Cancer (NSCLC): Used alone (monotherapy) for first-line treatment of metastatic NSCLC expressing PD-L1 (TPS ≥1%). Used in combination with chemotherapy for metastatic non-squamous and squamous NSCLC. Also indicated for neoadjuvant and adjuvant treatment of resectable NSCLC.
• Head and Neck Squamous Cell Carcinoma (HNSCC): Used alone or in combination with chemotherapy for first-line treatment of metastatic or recurrent HNSCC.
• Colorectal, Endometrial, and Other Solid Tumors: Indicated for unresectable or metastatic cancers that are Microsatellite Instability-High (MSI-H) or mismatch repair deficient (dMMR).
• Cervical, Gastric, Esophageal, Biliary Tract, and Renal Cell Carcinoma (RCC): Used for various stages and lines of therapy, often in combination with other agents or based on PD-L1 expression.
• Classical Hodgkin Lymphoma (cHL) & Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Treatment for refractory or relapsed disease after prior lines of therapy.

Non-oncological Uses

• No current FDA-approved non-oncological indications were found.

4. Dosage and Administration Protocols

Pembrolizumab is administered as an intravenous (IV) infusion over 30 minutes. Dose escalation or reduction is not recommended.

• 
  Dilution: Doses >100 mg should be diluted in 100{ mL} of sodium chloride 0.9%.
• Monitoring During Infusion: Patients should be monitored every 30 minutes during the infusion (blood pressure, pulse, and temperature) for infusion-related reactions.

Renal/Hepatic Dose Adjustments and Toxicity Management

Clinical Efficacy and Research Results (2020-2025 Context)

Pembrolizumab continues to show significant improvements in survival and response rates, particularly in biomarker-selected populations.

• Durable Response: Patients completing the full treatment course (35 cycles) exhibit promising outcomes, with 82.1% remaining alive at the five-year follow-up.
• Endometrial Cancer (dMMR/MSI-H): In dMMR/MSI-H endometrial cancer, pembrolizumab showed a significant improvement in progression-free survival (PFS) and overall survival (OS) compared to the proficient mismatch repair (pMMR) groups.
• Advanced NSCLC: Combination with chemotherapy led to improved patient outcomes compared to single-agent chemotherapy in patients with metastatic NSCLC (KEYNOTE-189 and KEYNOTE-407 trials). Real-world data supports its use even in PD-L1 negative advanced NSCLC, with an objective response rate (ORR) of 45.8%.
• Symptom Relief and Quality of Life: Patients receiving pembrolizumab have noted benefits including symptom relief, a quick response to treatment, and better health-related quality of life (HRQoL) than conventional treatments.

Safety Profile and Side Effects

Critical Safety Warning: Immune-Mediated Adverse Reactions

Pembrolizumab, due to its mechanism, can cause severe or fatal immune-mediated adverse reactions in any organ system or tissue, including the lungs, colon, liver, kidneys, and endocrine glands. These toxicities require prompt identification and management with systemic corticosteroids.

Common Side Effects (>10%)

• Systemic: Fatigue, decreased appetite, pruritus (itching), rash, diarrhea, constipation, nausea.
• Other: Musculoskeletal pain, cough, dyspnea (shortness of breath).
• Endocrine: Hypothyroidism or hyperthyroidism.

Serious Adverse Events

4. Immune-Mediated Pneumonitis: Inflammation of the lungs, including fatal cases, has occurred.
5. Immune-Mediated Colitis/Hepatitis/Nephritis: Severe inflammation of the colon, liver, or kidneys requires systemic immunosuppression and possible permanent discontinuation.
6. Endocrinopathies: Includes severe or life-threatening thyroid disorders, hypophysitis (pituitary inflammation), and Type 1 diabetes mellitus (including ketoacidosis).
7. Complications of Allogeneic HSCT: Fatal and other serious complications, including Graft-versus-Host Disease (GVHD), can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1 blocking antibody.

Connection to Stem Cell & Regenerative Medicine

Pembrolizumab’s role as an Immune Checkpoint Inhibitor (ICI) places it at the forefront of immunotherapy, often intersecting with cellular therapies like stem cell transplantation:

• Post-Allogeneic HSCT: Treatment with pembrolizumab after allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) is feasible and has shown efficacy in relapsed lymphoid malignancies. However, it is associated with a risk of severe immune-related adverse events (irAE), including exacerbated Graft-versus-Host Disease (GVHD).
• Pre- and Post-Autologous HSCT: Trials are testing how well pembrolizumab works when given both before and after an autologous stem cell transplant (ASCT) for relapsed/refractory Classical Hodgkin Lymphoma. Maintenance therapy with pembrolizumab following ASCT can help prevent or delay cancer from coming back.
• T-Cell Reactivation: By reactivating exhausted T-cells within the tumor microenvironment, pembrolizumab supports the core principle of regenerative medicine by enhancing the body’s own immune resources for sustained tumor elimination.

Patient Management and Practical Recommendations

Pre-treatment

• Biomarker Testing: A validated test is required to determine PD-L1 tumor status or MSI-H/dMMR status for specific indications.
• Organ Function: Blood tests must be performed to check the function of the liver, kidneys, and thyroid hormones before and during treatment.
• Immunosuppressants: Avoid the use of systemic corticosteroids or other immunosuppressants at baseline, as they can interfere with pembrolizumab’s efficacy.

Precautions During Treatment

• Toxicity Monitoring: Patients must be monitored vigilantly for any new symptoms, as initial irAE presentation can occur months after completion of treatment and affect multiple organs.
• Infusion Reactions: Monitor closely for fever, chills, dizziness, trouble breathing, or rash during the 30-minute infusion.
• Diarrhea Management: Promptly inform the care team of diarrhea. Take anti-diarrheal or steroid medication as directed and avoid spicy foods, dairy, high-fiber foods, and coffee.

Do’s and Don’ts

• DO:
  • DO: Contact your advice line immediately if you have signs of infection (temperature ≥37.5∘C or <36∘C), severe diarrhea, or trouble breathing.
  • DO: Immediately report symptoms of a serious liver problem (pain or tenderness in the upper stomach, dark urine, or yellow eyes/skin).
  • DO: Use effective contraception during treatment and for at least 4 months after your last dose.
• DON’T:
  • DON’T: Ignore signs of a severe or life-threatening side effect; early treatment can prevent permanent damage.
  • DON’T: Take systemic corticosteroids or immunosuppressants before starting pembrolizumab unless instructed.
  • DON’T: Breastfeed during treatment and for at least 4 months after your last dose.

Legal Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status, concurrent therapies, and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions and treatment plans.